BridGene Biosciences, Inc. announced that it will present a poster, titled “Preclinical characterization of BGI-9004, a covalent TEAD inhibitor with exceptional anti-cancer activity and combination potential,” at the American Association for Cancer Research (AACR) Annual Meeting 2023 on April 18 in Orlando.
April 17, 2023
· 2 min read
